NCT06317558View on ClinicalTrials.gov

Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

RecruitingOBSERVATIONAL
Enrollment

4,000

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

December 31, 2034

Conditions
NSCLC
Interventions
DRUG

Neoadjuvant immunotherapy

Immune checkpoint inhibitors are used as neoadjuvant settings for NSCLC patients.

DRUG

Other drugs for neoadjuvant treatment

Drugs other than immune checkpoint inhibitors are being used as a new adjuvant setting for patients with NSCLC.

Trial Locations (1)

100020

RECRUITING

Shugeng Gao, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER